Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC)
    Meeting Abstract

    Wander, S. A.; Weipert, C.; Liao, J.; Zhang, N.; Razavi, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Impact of clonal hematopoiesis on tumor control following radiation therapy
    Meeting Abstract

    Tao, J.; Setton, J.; Vela, P. S.; Safonov, A. M.; Comen, E. A.; Braunstein, L. Z.; Reis-Filho, J. S.; Riaz, N.; Powell, S. N.; Levine, R. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characterization of alpelisib-associated hyperglycemia in metastatic breast cancer
    Meeting Abstract

    Shen, S.; Chen, Y.; Carpio, A.; Chang, C.; Iyengar, N. M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC)
    Meeting Abstract

    Rugo, H. S.; O'Shaughnessy, J.; Jhaveri, K. L.; Tolaney, S. M.; Cardoso, F.; Bardia, A.; Maheshwari, V. K.; Tripathi, S.; Pathak, P.; Haftchenary, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer
    Meeting Abstract

    Safonov, A. M.; Bandlamudi, C.; Selenica, P.; Marra, A.; Ferraro, E.; Mandelker, D.; Solit, D. B.; Berger, M. F.; Norton, L.; Powell, S. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quantification of methylation-specific cardiomyocyte cell-free DNA as an early marker of cardiotoxicity in patients with breast cancer receiving anthracyclines and trastuzumab
    Meeting Abstract

    Moore, Z. R.; Yu, A. F.; Liu, J.; Dang, C. T.; Oeffinger, K. C.; Steingart, R.; Schmitt, A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; Park, D. J.; McAndrew, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
    Meeting Abstract

    Lu, J. M.; Kalinsky, K.; Tripathy, D.; Sledge, G. W.; Gradishar, W. J.; O'Regan, R.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer
    Meeting Abstract

    Lukashchuk, N.; Armenia, J.; Tobalina, L.; Carr, T. H.; Milenkova, T.; Liu, Y. L.; Penson, R. T.; Robson, M. E.; Harrington, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save